Stock Financial Ratios


BIO / Bio-Rad Laboratories, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price258.69
Volume119,700.00
Market Cap ($M)7,553.78
Enterprise Value ($M)7,581.06
Book Value ($M)2,490.50
Book Value / Share84.82
Price / Book2.89
NCAV ($M)3,270.19
NCAV / Share111.20
Price / NCAV2.81
Income Statement (mra) ($M)
Revenue2,019.44
EBITDA166.71
Net Income113.10
Balance Sheet (mrq) ($M)
Cash & Equivalents418.65
Cash / Share14.26
Assets2,695.53
Liabilities1,003.96
Quick Ratio2.92
Current Ratio4.03
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.03
Return on Equity (ROE)0.04
Identifiers and Descriptors
CUSIP090572207
Central Index Key (CIK)12208
Industry Groups
SIC 3826 - Laboratory Analytical Instruments
Other Related CUSIPS
090572957
090572907
Share Statistics
Common Shares Outstanding (M)24.30
Scoring Models
Piotroski F Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Other Current Per Share3.47
Current Portion Of Long Term Debt Per Share0.00
Cash Per Share14.26
Liabilities Per Share42.85
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share18.41
Liabilities Other Non Current Per Share14.13
Inventory Raw Materials Per Share3.87
Property Plant And Equipment Gross Per Share40.09
Debt Per Share14.77
Liabilities Current Per Share13.96
Minority Interest Per Share0.00
Additional Paid In Capital Per Share10.77
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Inventory Finished Goods Per Share10.20
Treasury Stock Per Share0.00
Retained Earnings Per Share62.51
Liabilities And Stock Equity Per Share131.75
Accounts Receivable Per Share12.45
Property Plant And Equipment Per Share15.56
Equity Per Share88.90
Goodwill Per Share17.18
Property Plant And Equipment Net Per Share15.56
Accumulated Depreciation And Depletion Per Share24.53
Intangibles Per Share7.84
Assets Other Non Current Per Share0.00
Assets Current Per Share61.40
Cash And Equivalents Per Share14.24
Assets Per Share131.75
Deferred Income Tax Liabilities Per Share0.00

Related News Stories

Bio Rad Laboratories (BIO) a Strong Buy on High-Level Quant Score

7h investorplace
With a $7.6 billion market value, Bio Rad Laboratories Inc (NYSE:BIO) ranks in the upper half of its industry group, Life Sciences Tools & Services, and in the top quarter of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's current Portfolio Grader score places it 1 among the 32 companies in this industry group, positioning it among the leaders; among the sector leaders with a ranking of 10 among the 781 companies in the sector, and number 69 in the nearly 5,000 company Portfolio Grader universe. (10-0)

Quant Score Metrics Drive Bio Rad Laboratories (BIO) to Strong Buy

2017-11-16 investorplace
Bio Rad Laboratories Inc (NYSE:BIO) is one of 33 companies within the Life Sciences Tools & Services GICS industry group, which is in turn part of the 782 company GICS Health Care sector. BIO has a market value of $7.7 billion which is in the top 25% of its industry group. The stock's current Portfolio Grader score places it 1 among the 33 companies in this industry group, putting it in the top decile; among the sector leaders with a ranking of 10 among the 782 companies in the sector, and number 69 in the nearly 5,000 company Portfolio Grader universe. (10-0)

Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx

2017-11-16 zacks
Illumina, Inc. (ILMN - Free Report) recently introduced its second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system — NextSeq 550Dx. The instrument has been designed to deliver the power of high-throughput NGS to the clinical laboratory. (55-0)

Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3

2017-11-13 zacks
Bio-Rad Laboratories, Inc. (BIO - Free Report) reported third-quarter 2017 earnings of 91 cents per share, a 46.8% surge from the year-ago figure. The bottom line also surpassed the Zacks Consensus Estimate of 33 cents by a wide margin. Notably, net income in the quarter was favorably impacted by higher sales and a significantly improved gross margin.  (36-0)

Rating on Bio Rad Laboratories (BIO) Raised to Strong Buy From a Buy

2017-11-09 investorplace
Currently, Bio Rad Laboratories Inc (NYSE:BIO) has a Strong Buy using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. BIO has been upgraded from a Buy to a Strong Buy in the last week. (10-0)

CUSIP: 090572207